RecruitingPhase 1NCT06943937
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
Studying Immune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
- Intervention
- YTS109 cell injection(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Beijing GoBroad Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06943937 on ClinicalTrials.govOther trials for Immune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07206758Phase I Study of SHR-2173 Injection in Patients With Primary Immune ThrombocytopeniaGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE1NCT07083960OM336 in Autoimmune CytopeniasOuro Medicines
- RECRUITINGPHASE4NCT07133659Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot StudyAl-Mustansiriyah University
- RECRUITINGNCT06727669Longitudinal Cohort of Thrombosis and Hemostasis DiseasesPeking University People's Hospital
- RECRUITINGPHASE2NCT06281327Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPHASE2NCT06199089A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06094881A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05757570An Open-label Study of Povetacicept in Participants With Autoimmune CytopeniasAlpine Immune Sciences, Inc.